Immutep Ltd
ASX:IMM
Immutep Ltd
Intangible Assets
Immutep Ltd
Intangible Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Intangible Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Immutep Ltd
ASX:IMM
|
Intangible Assets
AU$5.8m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-12%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Intangible Assets
$434.3m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-2%
|
|
|
CSL Ltd
ASX:CSL
|
Intangible Assets
$15.1B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
48%
|
CAGR 10-Years
32%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Intangible Assets
AU$2.4m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Intangible Assets
AU$393.8m
|
CAGR 3-Years
95%
|
CAGR 5-Years
48%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Intangible Assets
AU$3.8m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
Immutep Ltd
Glance View
Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. The company is headquartered in Sydney, New South Wales. The firm is engaged in the development of LAG-3 immunotherapeutic products for cancer and autoimmune disease. The firm has four product candidates based on the LAG-3 immune control mechanism. Its lead product candidate, eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein, which is in later-stage clinical development for the treatment of cancer. Its second product candidate (IMP761) is in pre-clinical development for the treatment of autoimmune disease. The Company’s two licensed product candidates include Antagonist AB (LAG525) and Depleting AB (GSK‘781). The Company’s operates through its subsidiaries, which includes Immutep USA Inc, PRR Middle East FZ LLC, Immutep GmbH, Immutep Australia Pty Ltd, Immutep IP Pty Ltd and Immutep S.A.S.
See Also
What is Immutep Ltd's Intangible Assets?
Intangible Assets
5.8m
AUD
Based on the financial report for Dec 31, 2025, Immutep Ltd's Intangible Assets amounts to 5.8m AUD.
What is Immutep Ltd's Intangible Assets growth rate?
Intangible Assets CAGR 10Y
-12%
Over the last year, the Intangible Assets growth was -24%. The average annual Intangible Assets growth rates for Immutep Ltd have been -16% over the past three years , -16% over the past five years , and -12% over the past ten years .
